Related by context. All words. (Click for frequent words.) 74 TG# [003] 70 bevasiranib 70 EVIZON 68 ASONEP 68 Sym# 67 Squalamine 67 Bendavia 67 preclinically 67 AzaSite Plus 67 Azedra 67 preclinical efficacy 67 JAK inhibitor 67 ocular formulation 67 Sphingomab 67 anti VEGF 67 anti angiogenic agent 66 PXD# 66 oral prodrug 66 vascular disrupting agents 66 Archexin 66 obatoclax 66 fosbretabulin 66 Perifosine 66 neovascular 66 liposomal formulation 66 VEGF inhibitors 66 squalamine 66 Traficet EN 66 pradefovir 66 CCX# 66 favorable pharmacokinetic profile 66 OXi# 65 huC# DM4 65 OHR/AVR# 65 tezampanel 65 vidofludimus 65 CA4P 65 ARIKACE ™ 65 JAK inhibitors 65 Azixa 65 EndoTAG TM -1 65 cannabinor 65 DXL# 65 Synavive 65 NGX# 65 pomalidomide 65 PDE4 inhibitor 65 Panzem R NCD 65 CORT # 65 PS# [001] 65 ENMD # 64 Onconase 64 Symadex 64 DexaSite 64 Relivar 64 selective androgen receptor modulator 64 incyclinide 64 HGS ETR1 64 Xanafide 64 Guanilib 64 vascular disrupting agent 64 proteasome inhibitor 64 Panzem 64 volociximab 64 Amplimexon 64 XmAb# 64 PSN# [002] 64 Aflibercept 64 Imprime PGG 64 OMP #M# 64 R#/MEM # 64 NXL# 64 metaglidasen 64 HCV protease inhibitors 64 KRN# 64 atacicept 64 NP2 Enkephalin 64 eltrombopag 64 HuLuc# 64 INCB# [001] 64 Bevasiranib 64 Phase Ib clinical 63 Bezielle 63 Tyrima 63 OncoVEX GM CSF 63 HuMax CD# 63 amrubicin 63 preclinical studies 63 Zybrestat 63 TELINTRA 63 NP2 63 #ME# 63 DR Cysteamine 63 dacetuzumab 63 Carfilzomib 63 Exelixis compounds 63 CRLX# 63 Aliskiren 63 investigational monoclonal antibody 63 NEUMUNE 63 phase IIb clinical 63 PEG SN# 63 MGd 63 immunomodulatory 63 AMPK activators 63 ATL# [001] 63 Spiegelmer ® 63 APOPTONE 63 Phase Ib study 63 vascular disrupting 63 elotuzumab 63 cilengitide 63 VDAs 63 JAK1 63 targeted radiotherapeutic 63 MAGE A3 ASCI 63 trabectedin 63 Bortezomib 63 geographic atrophy 63 mTOR inhibition 63 oxidative stress inducer 63 CGEN # 63 axitinib 63 TLK# 63 custirsen 63 ganetespib 63 phase IIa clinical 63 pegaptanib 63 MAP# 63 LHRH antagonists 63 LUCENTIS 63 VEGF Trap 63 AKT inhibitor 63 GLPG# 63 EVIZON ™ 63 mertansine 63 DFMO 63 Bioral 62 JAK2 inhibitor 62 Lpathomab 62 tanespimycin 62 HGS# 62 ecabet sodium 62 ANAVEX #-# [001] 62 octreotide implant 62 OvaRex R 62 ZYBRESTAT 62 EVIZON TM 62 radiation sensitizer 62 CBLC# 62 entinostat 62 ATL# [002] 62 Epratuzumab 62 CR# vcMMAE 62 Pimavanserin 62 CCR9 antagonist 62 PROMACTA 62 HuMax CD4 62 alvespimycin 62 AEG# 62 Tarvacin TM 62 HSP# inhibitor 62 HuMax EGFr 62 PD LID 62 Cethromycin 62 S1P antibody 62 receptor tyrosine kinase inhibitor 62 Seliciclib 62 iroxanadine 62 riociguat 62 Arimoclomol 62 Anavex #-# 62 MEK inhibitors 62 BZL# 62 PRX# 62 Mipomersen 62 tecarfarin 62 Aplidin 62 mTOR inhibitors 62 deforolimus 62 histone deacetylase HDAC inhibitor 62 Indaflex TM 62 OMNARIS HFA 62 elvucitabine 62 TACI Ig 62 Hsp# inhibition 62 ATL/TV# 62 RGB # 62 PhG alpha 1 62 Vilazodone 62 indibulin 62 Valortim 62 VA# [002] 62 fenretinide 62 orally administered inhibitor 62 p# inhibitor 62 Interferon alpha 62 diabetic macular edema DME 62 EndoTAGTM 1 62 choroidal neovascularization CNV 62 MGCD# [001] 62 GSK# [001] 62 blepharitis 62 cancer immunotherapies 62 GAP #B# 62 acetonide FA 62 SARMs 61 Hsp# inhibitors 61 LUVENIQ 61 OncoVEX 61 PRT# 61 Hsp# Inhibitor 61 mapatumumab 61 thymalfasin 61 Trofex 61 celgosivir 61 Chemophase 61 ARIKACE 61 Zoraxel 61 HspE7 61 targeting CD# 61 Hsp# inhibitor 61 Virulizin ® 61 nanoviricide 61 Tarvacin 61 TriRima 61 JAK3 61 immunomodulator 61 DDP# 61 TELCYTA 61 methylnaltrexone 61 Proxinium TM 61 choroidal neovascularization 61 UPLYSO 61 ostarine 61 iSONEP ™ 61 Ophthotech 61 BAY #-# 61 pharmacokinetic PK study 61 Cloretazine 61 ALN TTR# 61 BRAF inhibitor 61 docetaxel chemotherapy 61 Darusentan 61 Apoptone 61 Ophena TM 61 neratinib 61 Fibrillex TM 61 Vascugel 61 seliciclib 61 anti fibrotic 61 BEMA TM Fentanyl 61 delafloxacin 61 PSN# [001] 61 RhuDex ® 61 DermaVir Patch 61 ESBA# 61 Tarceva TM 61 Nanobody 61 YONDELIS 61 ON #.Na 61 CTA# 61 Viprinex 61 bortezomib Velcade 61 ISIS # 61 Phase 1b trial 61 nanoviricides 61 DAVANAT 61 Prodarsan ® 61 Bicifadine 61 PI3K inhibitor 61 anti amnesic 61 Diabetic Macular Edema 61 TKB# 61 Sphingomab TM 61 nonclinical studies 61 HGS ETR2 61 EKC Cide 61 tolevamer 61 nalbuphine ER 61 TKM ApoB 61 Factor VIIa 61 elacytarabine 61 lasofoxifene 61 IAP inhibitors 61 TRO# 61 bafetinib 61 TAFA# 61 bicifadine 61 MEK inhibitor RDEA# 61 Romidepsin 61 MAXY G# 61 Cannabinor 61 Cardio Vascu Grow 61 Aclidinium 61 aflibercept 61 Golimumab 61 bevacizumab Avastin ® 61 Cloretazine R VNP#M 61 CTAP# Capsules 61 prostone 61 Cerashield 61 romidepsin 61 RLY# 61 pexiganan 61 pharmacokinetic characteristics 61 Allovectin 7 ® 61 CINTREDEKIN BESUDOTOX 60 tezampanel NGX# 60 ThermoDox ® 60 CG# [003] 60 potent antiproliferative 60 Protectan CBLB# 60 sorafenib Nexavar 60 TBC# 60 IAP inhibitor 60 SRT# [003] 60 Multimeric 60 CRx 60 imexon 60 Phase 2a trial 60 cariprazine 60 SinuNase 60 NexACT 60 initiate Phase 1b 60 afamelanotide 60 decitabine 60 Zolinza 60 TH# [003] 60 AEGR 60 SERMs 60 GRN# 60 Akt inhibitor 60 Neurodex 60 SAR# [004] 60 orally bioavailable 60 Tavocept 60 demonstrated antitumor activity 60 immune modulating 60 Inhaled AAT 60 EDEMA3 trial 60 iSONEP TM 60 Tezampanel 60 Dasatinib 60 Phase #b/#a trial 60 Ceflatonin 60 MLN# 60 Onrigin 60 PEP# [003] 60 nanoviricide drug 60 chemotherapeutic drug 60 trastuzumab Herceptin R 60 Serdaxin 60 DuraSite 60 PEGylated 60 unoprostone isopropyl 60 Triolex 60 CCR5 antagonist 60 Daclizumab 60 trastuzumab emtansine T DM1 60 prokinetic agent 60 rifalazil 60 nanopharmaceutical 60 CD# monoclonal antibody 60 anti EGFR antibody 60 antisense drug 60 PI3K inhibitors 60 plasma kallikrein inhibitor 60 ELND# 60 Phase 1a clinical 60 INCB# [003] 60 erythropoietic 60 Nanobodies 60 PROCHYMAL 60 Glufosfamide 60 milatuzumab 60 Valortim ® 60 ZYBRESTAT fosbretabulin 60 INT# [002] 60 HQK 60 TRIOLEX 60 non nucleoside HCV 60 Allovectin 7 60 talabostat 60 Radilex 60 GALNS 60 Neuradiab 60 IMA# 60 latanoprost 60 Anturol TM 60 anti CD# antibodies 60 CIMZIA ™ 60 AQ4N 60 novel anticancer 60 CYT# potent vascular disrupting 60 Solulin 60 ganaxolone 60 Epanova 60 LEP ETU 60 PF # [001] 60 MDV# 60 Dapagliflozin 60 Elesclomol 60 2 methoxyestradiol 60 Tß4 60 Plasmin 60 HDAC Inhibitor 60 noninfectious uveitis 60 systemically administered 60 CaPre TM 60 TLR agonists 60 microplasmin 60 bexarotene 60 Ophena 60 ALN TTR 60 rilonacept 60 carboplatin paclitaxel 60 Tamibarotene 60 Liprostin 60 Phase 2a 60 velafermin belinostat 60 pharmacodynamic profile 60 PDE# inhibitors 60 talactoferrin 60 sirtuin modulators 60 davunetide intranasal AL 60 Lenocta 60 Phase IIa trials 60 photodynamic therapy PDT 60 Octreotide 60 #D#C# 60 DAVANAT R 60 menadione 60 tesmilifene 60 BNC# 60 GFT# 60 molecularly targeted 60 preclinical 60 PKC# 60 Nanobody ® 60 anti CD3 60 neuroprotective properties 60 Solazed TM 60 SinuNase TM 60 Omacetaxine 60 HepeX B 60 antisense oligonucleotide 60 Epothilones 60 Revimmune 60 gallium containing 60 successfully commercialize Iluvien 60 novel VDA molecule 60 Ostarine 60 topical antifungal 60 VIR# 60 RSD# oral 60 Prolacria 60 anticancer activity 60 masitinib 60 Silodosin 60 Tesetaxel 60 trodusquemine 60 otelixizumab 60 potency selectivity 60 Cytolin R 60 PI3K/Akt pathway inhibitor 60 Microplasmin 60 Alocrest 60 rHuPH# 60 Litx 60 Tekamlo 60 MYDICAR ® 60 INS# [001] 60 AP# [003] 60 evaluating tivozanib 60 Resten NG 60 ORE# 60 Elagolix 60 pertuzumab 60 CEQ# 60 Civacir 60 Targretin 60 cangrelor 60 ranibizumab 60 cediranib 60 ospemifene 60 Phenoptin 60 bazedoxifene 60 Curaxin 60 Thiarabine 60 Radezolid 60 Preclinical studies suggest 60 PCK# 60 corticosteroid dexamethasone 59 GW# [003] 59 viral kinetics 59 HIF PH inhibitors 59 enzastaurin 59 LibiGel ® 59 protein kinase inhibitor 59 ProSavin 59 Phase IIB 59 MP4OX 59 Zalypsis 59 valopicitabine 59 CIMZIA TM 59 NEUGENE antisense 59 RAPAFLO 59 intravitreal injection 59 endothelin receptor antagonists 59 Phase Ib clinical trials 59 EP #R 59 lixivaptan 59 Anticalins 59 antitumor activity 59 DB# [003] 59 Cethrin 59 Amrubicin 59 XL# XL# 59 dexpramipexole 59 Excellarate 59 Hedgehog antagonist 59 rxRNA 59 S/GSK# 59 BAL# [002] 59 tumor xenograft models 59 EOquin TM 59 Blinatumomab 59 phase IIa 59 histone deacetylase HDAC 59 Anticalins ® 59 Catena ® 59 ONCONASE R 59 Elotuzumab 59 Iloperidone 59 Altastaph 59 MEK inhibitor 59 adecatumumab 59 O PPDS 59 HCV protease 59 immune modulatory 59 ponatinib 59 synthetic retinoid 59 danoprevir 59 dose escalation Phase 59 Octreolin 59 orBec 59 histamine dihydrochloride 59 samalizumab 59 antiangiogenic 59 cMET 59 Aurora kinase 59 therapeutic monoclonal antibody 59 RDEA# 59 Ketotransdel 59 OvaRex ® MAb 59 triphendiol 59 KL4 surfactant 59 diabetic neuropathic pain 59 lorvotuzumab mertansine 59 OvaRex MAb 59 Fodosine 59 PEGylated interferon 59 HGS ETR1 mapatumumab 59 herpetic keratitis 59 tubulin inhibitor 59 ibudilast 59 BrachySil 59 Zenvia ™ 59 Phase #b/#a 59 TPI ASM8 59 TRAIL receptor antibodies 59 oral bioavailability 59 nucleoside analogues 59 T#I [002] 59 IMC A# 59 lomitapide 59 ACZ# 59 defensin mimetic antibiotic 59 Phase 1b clinical 59 aldehyde dehydrogenase ALDH2 deficiency 59 DACH platinum 59 diabetic macular edema 59 Kevetrin 59 Acute Radiation Syndrome ARS 59 Lu AA# 59 IPL# 59 Phase #b/#a clinical 59 Ranibizumab 59 telaprevir VX 59 Voreloxin 59 ceftazidime 59 microtubule targeting 59 NovaBay Aganocide compounds 59 pharmacodynamic properties 59 Randomized Phase 59 GSK# [002] 59 lintuzumab 59 class mGluR5 inhibitor 59 PLK1 SNALP 59 afatinib 59 Onalta 59 AZD# 59 Panzem R 59 EGS# 59 Doxil ® 59 Tolvaptan 59 anticancer agent 59 Talabostat 59 alagebrium 59 trastuzumab DM1 59 nitazoxanide 59 GLP toxicology studies 59 multitargeted 59 regorafenib 59 PARP inhibitor 59 L BLP# 59 Unit Dose Budesonide 59 ProLindac 59 exon skipping 59 Safinamide 59 torezolid phosphate 59 solithromycin 59 polymerase inhibitors 59 ThermoDox R 59 PDE# 59 Rescula 59 somatostatin analogue 59 AtuRNAi 59 CoFactor 59 LT NS# 59 aerosolized KL4 surfactant 59 oral rivaroxaban 59 generation FBPase inhibitor 59 #I TM# 59 proteasome inhibitors 59 Dalbavancin 59 PEG Interferon lambda 59 dextromethorphan quinidine 59 vemurafenib 59 cytostatic 59 Ostabolin C 59 glufosfamide 59 uric acid lowering 59 Phase #/#a 59 elesclomol 59 LY# [003] 59 GAMMAGARD 59 voclosporin 59 PLX cells 59 A3 adenosine receptor 59 efficacy endpoint 59 sapacitabine 59 calcitonin 59 Aurexis 59 FOLFOX6 chemotherapy regimen 59 elvitegravir 59 bevirimat 59 investigational humanized monoclonal antibody 59 anti angiogenic 59 GLP1 agonist 59 HDACi 59 quinolone 59 antifibrotic 59 PrevOnco 59 docetaxel Taxotere ® 59 confirmatory Phase III 59 denufosol 59 plasma pharmacokinetics 59 Protexia R 59 florbetaben 59 SIRT1 activators 59 XL# [003] 59 isoform selective 59 DOS# 59 daptomycin 59 PRX # 59 interferon gamma 1b 59 Davanat 59 immunomodulation 59 Nasulin 59 tolvaptan 59 INCB# [002] 59 bardoxolone methyl 59 trastuzumab DM1 T DM1 59 Trofex TM 59 Azedra TM 59 ciclesonide 59 Kahalalide F 59 intranasal formulation 58 Naproxcinod 58 plasma kallikrein 58 bendamustine 58 R#/MEM 58 Atiprimod 58 perifosine 58 bortezomib Velcade ® 58 siRNA therapeutic 58 Capesaris 58 VEGF Trap Eye 58 mecamylamine 58 pharmacodynamic profiles 58 IRX 2 58 DepoVax 58 VEGF inhibitor 58 PSMA ADC 58 JAK3 inhibitor 58 Aviptadil 58 HAAH 58 hGH CTP 58 SILENOR 58 Dacogen decitabine 58 Rigel R# 58 torezolid 58 TransVax ™ 58 rNAPc2 58 velafermin 58 Dicer Substrate Technology 58 FOLOTYN ® 58 erlotinib Tarceva ® 58 Fleximer 58 DCCR 58 EXPAREL TM 58 Hyphanox 58 laser photocoagulation 58 EGFR inhibitors 58 Pemetrexed 58 bevacizumab Avastin 58 OXIGON TM 58 isavuconazole 58 eniluracil 58 antiproliferative effects 58 Antiangiogenic 58 alemtuzumab MS 58 KNS # 58 Amphotericin B 58 SonoLysis 58 ALN RSV# 58 teduglutide 58 Spheramine 58 humanized anti 58 docetaxel Taxotere R 58 PDE4 inhibitors 58 Medidur 58 Optiquel ™ 58 novel immunomodulatory 58 thrombopoietin 58 PHX# 58 NEUGENE 58 Fulvestrant 58 anidulafungin 58 neovascular AMD 58 CXB# 58 CD# CEA 58 fluoropyrimidine 58 MoxDuo 58 ICA # 58 Orally administered 58 Doxorubicin 58 CBLB# 58 Luteinizing Hormone Releasing Hormone 58 M6G 58 NexACT ® 58 Anidulafungin 58 vivo efficacy 58 Hedgehog Pathway Inhibitor 58 STEDESA 58 hylan GF 58 BCR ABL inhibitors 58 omecamtiv mecarbil 58 subcutaneously administered 58 JAK2 inhibitors 58 PEGylated Fab fragment 58 Plicera 58 NLX P# 58 DermaVir 58 angiogenesis inhibitor 58 Cloretazine R 58 PDX pralatrexate 58 potent antitumor activity 58 nab paclitaxel 58 LymphoStat B TM 58 RPL# 58 CLORETAZINE TM VNP#M 58 anti angiogenic agents 58 Arcalyst 58 Pyridorin 58 oral antiviral 58 TORISEL 58 pain palliation 58 CCR5 inhibitor 58 ularitide 58 resolvin 58 rhThrombin 58 Palifosfamide 58 anticancer compound 58 nitric oxide donating prostaglandin 58 verteporfin 58 vismodegib 58 aurora kinase 58 HCV protease inhibitor 58 Denufosol 58 histone deacetylase inhibitor 58 potent anticancer 58 Pharmacokinetic studies 58 Maribavir 58 RAV# 58 Chemokine 58 GMX# 58 pegylated liposomal doxorubicin 58 delivered RNAi therapeutic 58 NVA# 58 tiapamil 58 KSP inhibitor 58 Moli# 58 pan HDAC inhibitor 58 CANCIDAS 58 Gleevec imatinib mesylate 58 phase IIb trial 58 BIBW 58 Iluvien ® 58 tafamidis 58 liposomal 58 Arikace 58 adenoviral 58 MET amplification 58 resolvins 58 anti leukemic 58 bardoxolone 58 Granulocyte Colony Stimulating Factor 58 PLX# 58 Abiraterone acetate 58 pimecrolimus 58 CINQUIL 58 Immunotherapeutic 58 oncolytic vaccine 58 gemcitabine Gemzar 58 REMURA 58 TOCOSOL Paclitaxel 58 baminercept 58 fibrotic disease 58 EndoTAG TM 58 siRNA therapeutics 58 Dextofisopam 58 ziconotide 58 esophageal candidiasis 58 XP# XP# 58 Allovectin 7 R 58 ART# 58 ZOLINZA 58 retapamulin 58 goserelin 58 alkylating agent 58 IFN α 58 Linaclotide 58 NEVO ™ 58 Phase Ib 58 AVE# 58 paclitaxel Taxol ® 58 forodesine 58 KB# [002] 58 pharmacodynamic effects 58 calcineurin inhibitors 58 LB# [003] 58 double blinded placebo 58 SAR# [002] 58 TLR9 agonist 58 Cytolin ® 58 small molecule Hedgehog 58 Chrysalin 58 radezolid 58 delivers fluocinolone acetonide FA 58 analgesic efficacy 58 RNAi therapeutic targeting 58 Tumor Necrosis Factor 58 anti angiogenic drugs 58 ZK EPO 58 evaluating satraplatin 58 Darinaparsin 58 reslizumab 58 Cetrorelix 58 Zyclara 58 Preclinical studies 58 BHT DNA 58 anticancer therapy 58 compound AEZS 58 IDX# 58 tumor vascular disrupting 58 hypoxia selective 58 Exherin TM 58 TREANDA 58 Phase IIb clinical trials 58 renin inhibitor 58 farletuzumab 58 Tanespimycin 58 novel oral anticoagulant 58 ranibizumab Lucentis 58 octreotide acetate 58 Solazed ™ 58 Corlux 58 pharmacodynamic PD 58 REG1 58 docetaxel prednisone 58 Angiolix 58 acyclovir Lauriad R 58 COPREXA 58 DP b# 58 R roscovitine 58 imetelstat 58 Glypromate 58 kinase inhibitors 58 Gemcitabine 58 antiangiogenic agents 58 tamibarotene 58 RTP #i 58 CCX# B 58 sodium glucose cotransporter 58 IL #E 58 Targeted Chemotherapy 58 MKC# MKC# PP 58 Phase IIa clinical 58 Innovive 58 BioSilicon 58 canakinumab 58 Photodynamic therapy PDT 58 Mpex 58 ALN PCS 58 Aganocide ® 58 Combidex 58 Valortim R 58 PEG PAL 58 Annamycin 58 Ozarelix 58 immune stimulatory 58 miglustat 58 PORxin TM 58 Personalized Immunotherapy 58 Ceplene/IL-2 58 rBChE 58 Novolimus 58 EOquin 58 Phase 2a Clinical Trial 58 liposomal doxorubicin 58 Dacogen injection 58 denufosol tetrasodium 58 JAK#/JAK# 58 LEVADEX TM 58 dose proportionality 58 ongoing Phase 1b 58 tasocitinib 58 Anthim 58 Restanza 58 Meets Primary Endpoint 58 Neovascular 58 galiximab 58 solanezumab 58 iobenguane 58 torsemide ER 58 myeloproliferative diseases 58 Vernakalant 58 ImmunoVEX HSV2 58 pralatrexate 58 Laquinimod 58 palifosfamide 58 Ebola SNALP 58 Pathway Inhibitor 58 Anticalin 58 DEB# 58 Posiphen 58 Sapacitabine 58 multiple myeloma MM 58 timolol 58 PROSTVAC TM 58 small molecule defensin 58 fenofibric acid 58 Bafetinib 58 Pralatrexate 58 EGFR tyrosine kinase inhibitors 58 Pliaglis 58 neuroprotectant 58 HZT 58 Anti VEGF 58 Anticalins R 58 LymphoStat B belimumab 58 oral talactoferrin 58 Teriflunomide 58 CRD5 58 nucleoside 58 MAb 58 Solazed 58 Aganocide R 57 Phase 2b study 57 AAG geldanamycin analog 57 tacrolimus ointment 57 Cobalamin 57 VAPRISOL 57 SCCHN 57 Hedgehog inhibitor 57 Diabetic Macular Edema DME